The filing content provided is primarily the cover page, table of contents, and forward-looking statements cautionary language of Biogen Inc.'s Form 10-Q for the period ended September 30, 2026. The substantive financial disclosure content (financial statements, MD&A figures, specific results) is not included in the extracted text beyond boilerplate and forward-looking statement disclaimers. However, there are enough specific facts (share count, company identity, filing period, product names, acquisition details) to exceed 150 words of substantive content.

Biogen Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on October 28, 2026, covering the three- and nine-month periods ended September 30, 2026.

Key Highlights

  • Share count: As of October 26, 2026, Biogen had 147,820,223 shares of Common Stock, $0.0005 par value, outstanding.
  • Large accelerated filer: The company indicated it is classified as a large accelerated filer under Rule 12b-2 of the Exchange Act.
  • Key products named: The filing identifies LEQEMBI, SKYCLARYS, EMPAVELI, SYFOVRE, TECFIDERA, and TYSABRI among products discussed in connection with revenue dependence and competitive risk disclosures.
  • Pipeline candidates highlighted: The filing specifically names felzartamab and litifilimab as significant pipeline and investment priorities.
  • Acquisitions referenced: The filing references the company's acquisitions of Reata, HI-Bio, and Apellis and states anticipated benefits include future performance of SKYCLARYS, EMPAVELI, and SYFOVRE products.
  • Competitive risk flagged: The filing cites increased competition from TECFIDERA generic entrants in U.S. and international markets, and a biosimilar entrant of TYSABRI, as risk factors.

Biogen's September 2026 Quarterly Filing: Products, Pipeline, and Key Disclosures

Biogen Inc. (NASDAQ:BIIB), a biopharmaceutical company headquartered at 225 Binney Street, Cambridge, Massachusetts 02142, submitted its Form 10-Q for the quarterly period ended September 30, 2026. The filing covers both three-month and nine-month periods ending on that date and was made under Commission File Number 0-19311. The company's common stock is listed on The Nasdaq Global Select Market under the trading symbol BIIB.

According to the filing, the company's outstanding share count stood at 147,820,223 shares of Common Stock, $0.0005 par value, as of October 26, 2026. The registrant confirmed it is not a shell company, is not an emerging growth company, and has filed all required reports under the Securities Exchange Act of 1934 during the preceding 12 months, the filing disclosed.

The filing identifies several products central to the company's revenue base, including LEQEMBI and SKYCLARYS, and notes that the company's financial performance is substantially dependent on the anticipated amount, timing, and accounting of revenue from its products. On the acquisition front, Biogen disclosed its prior acquisitions of Reata, HI-Bio, and Apellis, and indicated anticipated future performance of the SKYCLARYS, EMPAVELI, and SYFOVRE products as part of expected benefits from those transactions. The filing also describes felzartamab and litifilimab as subjects of significant pipeline investment. Competitive pressures referenced include generic entrants for TECFIDERA in U.S. and international markets and a biosimilar entrant of TYSABRI. The filing notes that forward-looking statements contained in the report are made pursuant to the Private Securities Litigation Reform Act of 1995 and are subject to the company's cautionary language regarding risks and uncertainties, many of which the filing describes as "outside of our control."

What Was Disclosed

Biogen Inc. filed its Form 10-Q for the quarter ended September 30, 2026, disclosing 147,820,223 shares outstanding as of October 26, 2026, and identifying key products, pipeline candidates, and acquisition-related disclosures as part of its quarterly reporting obligations.